Oramed Pharmaceuticals Inc.
ORMP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 8/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.15 | -0.51 | -0.64 |
| FCF Yield | -8.53% | -11.33% | -6.06% | -3.85% |
| EV / EBITDA | -3.01 | 18.54 | -11.62 | -19.31 |
| Quality | ||||
| ROIC | -10.24% | -7.21% | -26.07% | -17.45% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.44 | -2.02 | 0.74 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -20.86% | -0.09% | 0.00% |
| Free Cash Flow Growth | 20.09% | 62.87% | -31.81% | -72.15% |
| Safety | ||||
| Net Debt / EBITDA | 3.63 | 5.81 | 1.07 | 3.06 |
| Interest Coverage | -14.98 | -4.40 | 0.00 | -4,037.17 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,492.15 | 0.00 | 0.00 | 0.00 |